Literature DB >> 32229735

Microenvironment-Derived FGF-2 Stimulates Renal Cell Carcinoma Cell Proliferation through Modulation of p27Kip1: Implications for Spatial Niche Formation and Functional Intratumoral Heterogeneity.

Weibin Hou1, Adam Kaczorowski1, Philippa Lantwin1, Maximilian Kippenberger1, Viktoria Schütz2, Desiree Franke2, Svenja Christina Dieffenbacher2, Markus Hohenfellner2, Stefan Duensing3,4.   

Abstract

BACKGROUND/
OBJECTIVE: Clear cell renal cell carcinoma (ccRCC) is characterized by a high degree of functional intratumoral heterogeneity (ITH). This is highlighted by the finding that tumor cell proliferation and intracellular signaling occur preferentially in the tumor periphery. The driving forces for such a spatial organization are largely unknown. Herein, we investigate the role of the tumor microenvironment in the control of tumor cell proliferation and functional ITH.
METHODS: Conditioned media (CM) derived from nonmalignant peritumoral kidney tissue were used to stimulate RCC cells in vitro. A neutralization assay was used to characterize the role of FGF-2 in the CM. The molecular mechanisms underlying the action of CM on RCC cells were investigated using immunoblotting, flow cytometry and immunofluorescence microscopy. Lastly, a series of ccRCCs were stained for Ki-67 and p27Kip1, and expression was analyzed in both tumor periphery and center.
RESULTS: We show that CM derived from nonmalignant kidney cells adjacent to an RCC can downregulate the expression of the CDK inhibitor p27Kip1 through enhanced protein degradation in an FGF-2-dependent fashion. FGF-2 functions mainly through the PI3K/AKT pathway downstream of its receptors, and RCC cells with constitutively high AKT activity show not only an enhanced degradation of p27Kip1 through the Emi1-Skp2 axis, but also a subcellular mislocalization of p27Kip1 to the cytoplasmic compartment. Such a mislocalization was also detected in the tumor periphery in vivo suggesting that p27Kip1 plays an important role in shaping this spatial niche.
CONCLUSIONS: Our results suggest that the tumor microenvironment is involved in shaping the tumor peripheral niche by stimulating the enhanced proliferation that is characteristic for this zone. The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  FGF-2; Renal cell carcinoma; Spatial niche; Tumor heterogeneity; Tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 32229735      PMCID: PMC7265770          DOI: 10.1159/000506709

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  26 in total

1.  Hypoxia inhibits mesenchymal stem cell proliferation through HIF1α-dependent regulation of P27.

Authors:  Sanjay Kumar; Meenal Vaidya
Journal:  Mol Cell Biochem       Date:  2016-02-26       Impact factor: 3.396

2.  A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.

Authors:  Thomas Powles; Shah-Jalal Sarker Foreshew; Jonathan Shamash; Naveed Sarwar; Simon Crabb; Anju Sahdev; Jude Nixon; Louise Lim; Ashish Pungaliya; Abigail Foreshaw; Rachel Davies; Michelle Greenwood; Peter Wilson; Simon Pacey; Myra Galazi; Robert Jones; Simon Chowdhury
Journal:  Eur J Cancer       Date:  2014-06-04       Impact factor: 9.162

3.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

4.  Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

Authors:  Robert J Motzer; Camillo Porta; Nicholas J Vogelzang; Cora N Sternberg; Cezary Szczylik; Jakub Zolnierek; Christian Kollmannsberger; Sun Young Rha; Georg A Bjarnason; Bohuslav Melichar; Ugo De Giorgi; Viktor Grünwald; Ian D Davis; Jae-Lyun Lee; Emilio Esteban; Gladys Urbanowitz; Can Cai; Matthew Squires; Mahtab Marker; Michael M Shi; Bernard Escudier
Journal:  Lancet Oncol       Date:  2014-02-17       Impact factor: 41.316

5.  mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.

Authors:  Feng Hong; Michelle D Larrea; Cheryl Doughty; David J Kwiatkowski; Rachel Squillace; Joyce M Slingerland
Journal:  Mol Cell       Date:  2008-06-20       Impact factor: 17.970

6.  A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity.

Authors:  Bartlomiej Waclaw; Ivana Bozic; Meredith E Pittman; Ralph H Hruban; Bert Vogelstein; Martin A Nowak
Journal:  Nature       Date:  2015-08-26       Impact factor: 49.962

7.  Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma.

Authors:  Catherine Denicourt; Cheryl C Saenz; Brian Datnow; Xian-Shu Cui; Steven F Dowdy
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.

Authors:  Bernard Escudier; Viktor Grünwald; Alain Ravaud; Yen-Chuan Ou; Daniel Castellano; Chia-Chi Lin; Jürgen E Gschwend; Andrea Harzstark; Sarah Beall; Nicoletta Pirotta; Matthew Squires; Michael Shi; Eric Angevin
Journal:  Clin Cancer Res       Date:  2014-04-01       Impact factor: 12.531

9.  Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation.

Authors:  D Zhao; A H Besser; S A Wander; J Sun; W Zhou; B Wang; T Ince; M A Durante; W Guo; G Mills; D Theodorescu; J Slingerland
Journal:  Oncogene       Date:  2015-02-16       Impact factor: 9.867

Review 10.  Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications.

Authors:  Marco Gerlinger; James W Catto; Torben F Orntoft; Francisco X Real; Ellen C Zwarthoff; Charles Swanton
Journal:  Eur Urol       Date:  2014-05-02       Impact factor: 20.096

View more
  3 in total

Review 1.  Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities.

Authors:  Laura Pohl; Jana Friedhoff; Christina Jurcic; Miriam Teroerde; Isabella Schindler; Konstantina Strepi; Felix Schneider; Adam Kaczorowski; Markus Hohenfellner; Anette Duensing; Stefan Duensing
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

Review 2.  Cancer heterogeneity and metastasis: life at the edge.

Authors:  Robert J Gillies
Journal:  Clin Exp Metastasis       Date:  2021-05-17       Impact factor: 5.150

3.  Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma.

Authors:  Alexander Bondoc; Kathryn Glaser; Kang Jin; Charissa Lake; Stefano Cairo; James Geller; Gregory Tiao; Bruce Aronow
Journal:  Commun Biol       Date:  2021-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.